The rising prevalence of multiple myeloma is pushing up the demand for therapy. A person, for example, has a 1 in 111 (or 0.90%) chance of being diagnosed with multiple myeloma by the age of 85 (1.1% for men and 0.74% for women). As a result of the predicted increase in the number of people suffering from multiple myeloma, the company's focus on creating effective and safe treatments is expected to quicken. The multiple myeloma diagnostic industry is growing increasingly competitive, with businesses such as Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., and BD serving as the primary market leaders in the United States.
Data Bridge Market Research analyses a growth rate in the Multiple Myeloma Diagnostic Market in the forecast period 2023-2030. The expected CAGR of multiple myeloma diagnostic market is tend to be around 5.40% in the mentioned forecast period. The market value is USD 6.36 billion in 2022, and it would grow up to USD 9.7 billion by 2030.
“Growing cases of obesity is bolstering the market growth”
Stroke, type 2 diabetes, heart disease, and some types of cancer are all obesity-related illnesses. These are among the leading causes of unnecessary death. Obesity was prevalent in 39.8% of persons aged 20 to 39 years, 44.3% of those aged 40 to 59 years, and 41.5% of adults aged 60 and more. Obesity affects more than two out of every five persons. In 2020, the prevalence of obesity in the United States was 41.9%. Obesity's rising prevalence is aiding the disease's progression and boosting the rate of diagnosis. As a result, the market grows.
What restraints the growth of the U.S Multiple Myeloma Diagnostic Market?
“High costs associated will restrain the market growth"
A variety of diagnostic techniques are associated with the condition, including blood testing, urine tests, and bone marrow examination. Myeloma cells are discovered in bone marrow and imaging tests using fluorescence in situ hybridization. This diagnostic method increases the pace of expense. As a result, these factors limit market expansion.
Segmentation: U.S Multiple Myeloma Diagnostic Market
The market is segmented into seven segments based on disease, test type, type, end user and distribution channel.
- On the basis of disease, the market is segmented into smouldering (indolent) multiple myeloma, active (symptomatic) multiple myeloma, solitary plasmacytoma of the bone, extrameduallry plasmacytoma, light chain myeloma, non-secretory myeloma and rare types of myeloma.
- On the basis of test type, the market is segmented into blood tests, urine tests, bone marrow tests and genome sequencing in multiple myeloma.
- On the basis of type, the market is segmented into devices and consumables and reagents.
- Based on end user, the market is segmented into hospitals, specialty clinics, academic and research institutes and others.
- Based on distribution channel, the market is segmented into retail pharmacy & drug store, hospital pharmacy, online pharmacy, others.
To know more about the study, visit, https://www.databridgemarketresearch.com/zh/reports/us-multiple-myeloma-diagnostic-market
The Prominent Key Players Operating in the U.S Multiple Myeloma Diagnostic Market Include:
- CareFusion (U.S.)
- C.R. Bard (U.S.)
- Straub Medical AG (U.S.)
- FlowJo LLC (U.S.)
- NeoGenomics Laboratories (U.S.)
- Helena Laboratories Corporation (U.S.)
- Bracco (Italy)
- ZYTOVISION GmbH (Germany)
- Adaptive Biotechnologies. (U.S.)
- BioVendor R&D (U.S.)
- TriVitron Healthcare (India)
- Eurofins Discovery (France)
- Quest Diagnostic Incorporated (U.S.)
Above are the key players covered in the report, to know about more and exhaustive list of U.S multiple myeloma diagnostic market companies contact, https://www.databridgemarketresearch.com/zh/contact
Research Methodology: U.S Multiple Myeloma Diagnostic Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, global vs regional and vendor share analysis. Please request analyst call in case of further inquiry.
